Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a ...
Protect cash flow. “Rising costs can create a timing problem, especially when businesses have to pay more for inventory, ...
CrowdStrike’s 2026 Threat Hunting Report has revealed a sharp escalation in cyber and AI‑enabled attacks against financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results